Cantilever-centric mechanism of cooperative non-active site mutations in HIV protease: Implications for flap dynamics.
PMID: 34030114
2021
Journal of molecular graphics & modelling
Abstract: The HP3 PR contained the I13V, I62V, and V77I mutations while HP4 PR contained the same mutations with the addition of the L33F mutation.
Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
Result: This resistance test revealed infection with HIV-1 subtype B and the presence of the accessory mutations M36I, I62V, and V77I not causing any clinically relevant resistance to antiretroviral drugs.
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.
PMID: 32556165
2020
The Journal of antimicrobial chemotherapy
Table: V77I
HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases.
PMID: 30798679
2019
Journal of the International Association of Providers of AIDS Care
Conclusion: The genotype performed at this time showed the following protease inhibitor gene mutations: I13I/V, E35D, D60E, L63P, I64V, and V77I and RT mutation V106I/V/M conferring resistance to efavirenz and nevirapine.
Conclusion: The genotype report at that time showed protease gene mutations L63P and V77I, and the patient had prior exposure to zidovudine, lamivudine, didanosine, and nevirapine, since her diagnosis in 2004.
HIV-1 Protease Evolvability Is Affected by Synonymous Nucleotide Recoding.
Abstract: However, the WT and MAX virus proteases showed different resistance variant repertoires, with the G16E and V77I substitutions observed only in the WT and the L33F, S37P, G48L, Q58E/K, and L89I substitutions detected only in the MAX virus.
A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011.
Result: The 3 most prevalent HIV-1 resistance-associated mutations for PRO were L63P (73.9%), V77I (45.2%) and I13V (34.2%), whereas I50L, I50V and K20I were the least abundant mutations recorded during the 10-year period (Figs 2 and 4).
Discussion: The V77I mutation facilitates increased drug resistance by providing conformational flexibility to the enzyme.
Discussion: The second most frequent PRO mutation that we observed in Puerto Rico-V77I -is considered to be one of the most prominent non-active site mutations implicated in antiretroviral drug resistance.
Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India.
Result: Only 1 individual had major PI resistance mutation L90M and 5 had minor PI resistance mutations L89M, V77I, L63P, H69K/R/Q, M36I, K20I/M/R/T, G16E, and L10V/I.
Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance.
8Discussion: The observed low abundances of A62VRT (8.3%) and V77IPR (11.4%) among the HIV-1 variants in TO may result from importation of WT HIV-1 to this area followed by prevalent
Result: On the other hand, only the A62VRT mutation of the DR mutations in the pol gene specific of HIV-1 subtype IDUA (V77IPR and A62VRT) was detected at a rate of 8.3%.
Discussion: The circulating subtype A HIV-1 variants characteristic of Russia are those carrying the V77IPR and/or A62VRT mutations and wild-type (WT) HIV-1.
Discussion: The mutations A62VRT and V77IPR are certain marker mutations for the subtype A HIV-1 variants circulating in Russia.
Structural Studies of a Rationally Selected Multi-Drug Resistant HIV-1 Protease Reveal Synergistic Effect of Distal Mutations on Flap Dynamics.
HIV mutation literature information.
PMID: 
2021
Journal of molecular graphics & modelling
Browser Board
Co-occurred Entities
Filtrator
ViMRT